AI drug discovery may be finding its real scaling law. 🧬
As Claude and other frontier models move deeper into biology, the bottleneck is shifting from model capability to proprietary biological data and real-world feedback.
That puts companies with unique data assets in focus. $TEM, for example, has built 500+ PB of molecular and clinical data across 45M+ de-identified patient journeys.
The next AI drug race may be less about who has the biggest model — and more about who can build the fastest data → prediction → validation → feedback loop.
Trade $TEM on StableStock:
→
#
AIDrugDiscovery# #
Biotech# #
TEM#
Not investment advice. For informational purposes only.